The present disclosure provides yeast screening system/s and methods for screening of candidate therapeutic compound/s for treating, at least one proteniopathy and/or protein misfolding disorder. More specifically, the present disclosure provides systems and methods for identifying a therapeutic compound that inhibit Hcy fibril formation and uses thereof in treating Alzheimer's disease.

A method for screening secretion-producing cells is provided, in which a cell that produces a secretion of interest is subjected to screening from a plurality of cells. The method includes capturing the cell and at least one detection particle that is allowed to capture the secretion of interest in each of a plurality of wells having a bottom section with a through-hole sized such that the cell does not pass through, causing the cell captured in each of the plurality of wells to produce a secretion, detecting the secretion of interest captured by the at least one detection particle, and identifying, based on a result of the detection as an index, a well in which a cell producing the secretion of interest is captured from the plurality of wells. Each of the wells has a size allowing the cell to be captured in one cell unit in a state in which one or more detection particles are captured.

A method, a composition and a kit for screening an ALK or ROS-1 kinase inhibitor are disclosed in the present specification. In an aspect, by the method, composition and kit for screening an ALK or ROS-1 kinase inhibitor according to the present disclosure, it is possible to conduct simultaneous quantitative and qualitative analysis and faster screening of a larger number of candidate substances as compared with conventional molecular biological experimental methods and to grasp the overall level of change in a plurality of different metabolites in a cell line by candidate substances of ALK or ROS-1 kinase inhibitor and thus the screening efficiency for drugs which exert an ALK or ROS-1 kinase inhibitory effect is excellent. Consequently, the present disclosure has an advantage of being able to be used in various ways in the development of new drugs which exert an ALK or ROS-1 kinase inhibitory effect.

The present disclosure, in some aspects, is directed to methods for screening and identifying compounds that modulate one or more characteristics associated with a condensate comprising a RBM20 polypeptide and/or the RBM20 polypeptide. In other aspects, the disclosure is directed to systems and composition components thereof, such as cellular models useful for the methods described herein.

The present invention relates to a method for measuring the cholesterol uptake capacity of lipoproteins. The present invention also relates to a reagent kit for measuring the cholesterol uptake capacity of lipoproteins. The present invention further relates to a tagged cholesterol which can be used in the method and the reagent kit.

The present invention relates to systems, kits, and methods for identifying subjects with increased levels of phenylacetyl glutamine (PAG) or the combination of PAG and trimethylamine-n-oxide (TMAO) and/or N6-trimethyl-lysine (TML), and/or PSA, pp and/or betaine, and/or choline, as well as methods of determining risk of disease (e.g., CVD, heart failure, asthma, diabetes, thrombosis, and lethal prostate cancer) based on such levels. In certain embodiments, the subjects are free of chronic kidney disease and/or have type II diabetes. In particular embodiments, subjects are treated with a therapeutic, such as a beta-adrenergic blocking agent, an alpha 2 adrenergic receptor agonist, an alpha 2 adrenergic receptor antagonist, an antibiotic or antibiotic cocktail, or a prostate cancer therapeutic. In certain embodiments, the subject is treated with a procedure such as brachytherapy, radiation therapy, or prostatectomy.

The disclosure relates to compositions comprising PU.1 inhibitors as well as methods of making and using the same. In some embodiments, methods of screening compounds for PU.1 inhibition are disclosed. In some embodiments, methods of screening a plurality of compounds for PU.1 inhibition are disclosed. In some embodiments, lambda-beta binding (LBB) motifs are used to screen compounds for PU.1 inhibition. In some embodiments, methods of treating neurodegenerative disorders are disclosed. In some embodiments pharmaceutical compounds are provided. In some embodiments, methods of treating Alzheimer's disease, inflammation, or excessive myelin uptake with PU.1 inhibitors are disclosed.

The present invention relates to methods for detecting the presence or absence of Parkinson's disease (PD).

Disclosed herein are methods and systems for evaluating the bioenergetic poise and bioenergetic capacity of living cells in a single assay.

The present invention provides a method for screening a substance that controls APP669 N-terminal cleavage activity, the method comprising: causing a candidate substance to act on a cultured cell; measuring an AP-related peptide produced from the cultured cell; and evaluating APP669 N-terminal cleavage activity. The candidate substance is selected, for example, from the group consisting of a low molecular weight compound, a peptide, a protein, and a nucleic acid. The present invention also provides an APP669 N-terminal cleavage enzyme containing ADAMTS4.